For the first time in Medicare's history, the program will cover GLP-1 medications for weight loss. The Medicare GLP-1 Bridge — a short-term demonstration running from July 1, 2026 through December 31, 2027 — will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs for obesity and overweight with weight-related conditions.
This is a significant shift. Medicare had historically excluded anti-obesity medications from coverage under a statutory bar that stood for decades. The Treat and Reduce Obesity Act (TROA) removed that bar, and the GLP-1 Bridge is the first concrete implementation of that change. Here's what you need to know as a patient — and what it means for the broader telehealth landscape.
What the Bridge Program Is
The Medicare GLP-1 Bridge is a short-term demonstration run by the Centers for Medicare & Medicaid Services (CMS). It operates outside the regular Medicare Part D benefit structure, meaning Part D plan sponsors do not carry risk for GLP-1 drugs furnished through the Bridge. This is important because it means your Part D plan doesn't need to opt in — the Bridge operates independently.
CMS announced the program in December 2025 as part of the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive Health) model. The Bridge serves as a transitional mechanism while CMS collects utilization data and prepares for potential longer-term integration of GLP-1 coverage into Part D.
The program runs nationwide across all states and territories, and was initially set to end December 31, 2026 before being extended through December 31, 2027.
Who's Eligible
To qualify for the Medicare GLP-1 Bridge, a beneficiary must be enrolled in a Medicare Part D plan, and a provider must submit a prior authorization request attesting that the patient is being prescribed the medication to reduce excess body weight and maintain weight reduction, in combination with current and ongoing lifestyle modification including structured nutrition and physical activity — consistent with the FDA-approved label for the prescribed medication.
The program covers FDA-approved GLP-1 medications indicated for chronic weight management. This includes Wegovy (semaglutide), Zepbound (tirzepatide), and Foundayo (orforglipron) — all FDA-approved for weight loss in adults with obesity or overweight with at least one weight-related comorbid condition.
How It Works at the Pharmacy
The Medicare GLP-1 Bridge operates through a central processor rather than through individual Part D plans. Pharmacies will be reimbursed by the central processor at the wholesale acquisition cost of the drug, minus the beneficiary copay, plus a dispensing fee and applicable sales tax.
For patients, this means you'll fill your prescription at a participating pharmacy and pay a copay. CMS has not yet finalized the specific beneficiary cost-sharing amounts as of this writing, but the program is designed to make GLP-1 medications affordable for Medicare beneficiaries. Eli Lilly has separately indicated that eligible Medicare Part D patients may have access to Foundayo for around $50 per month beginning July 1, 2026.
If your Part D plan does not cover a GLP-1 medication and you submit a prior authorization request, CMS has strongly encouraged plan sponsors to direct providers to the Bridge program's central processor. The goal is to create a smooth referral pathway so patients don't fall through the cracks.
What This Means for Telehealth
The Medicare GLP-1 Bridge has significant implications for the telehealth GLP-1 market:
Compounded alternatives face new competition
Many Medicare beneficiaries who turned to compounded GLP-1 medications did so because Medicare didn't cover the brand-name versions. With the Bridge program, eligible beneficiaries will be able to access FDA-approved medications at potentially lower out-of-pocket costs than compounded alternatives. This may reduce demand for compounded products among the Medicare population.
Telehealth providers can participate
CMS has confirmed that providers do not need to be enrolled in Medicare to write prescriptions or submit prior authorization requests under the Bridge program. However, the provider must not be on the CMS Preclusion List. This means telehealth prescribers can participate, provided they meet the program's clinical requirements.
Prior authorization is required
Every prescription under the Bridge requires prior authorization. The provider must attest that the beneficiary meets eligibility criteria and that the prescription includes lifestyle modification requirements consistent with the FDA label. Telehealth platforms that serve Medicare patients will need prior authorization infrastructure — something not all currently have.
The data collection matters
CMS is explicitly using the Bridge to collect utilization data for GLP-1 medications among Medicare beneficiaries. This data will inform decisions about whether and how to integrate GLP-1 coverage into the regular Part D benefit structure long-term. The Bridge is temporary, but the coverage expansion it represents may become permanent based on the evidence gathered.
What the Bridge Does Not Cover
The Bridge program has important limitations:
Compounded medications are excluded. Only FDA-approved GLP-1 drugs are eligible. If you're currently using a compounded GLP-1 through a telehealth platform, the Bridge won't cover that product. You would need to switch to an FDA-approved medication to use the Bridge.
Not all GLP-1s are included. The program covers medications approved for chronic weight management specifically. GLP-1 drugs approved only for diabetes (like Ozempic and Mounjaro) would need to be covered through the regular Part D benefit for their approved indications.
Lifestyle modification is required. The FDA labels for these medications require them to be used in combination with a reduced-calorie diet and increased physical activity. The prior authorization process will require provider attestation that these lifestyle components are part of the treatment plan.
How to Prepare If You're a Medicare Beneficiary
If you're on Medicare and interested in GLP-1 medication for weight loss, here are practical steps to take before the Bridge program launches in July:
Talk to your provider now. Whether you see a primary care physician, specialist, or telehealth provider, discuss your interest in GLP-1 treatment and confirm they're willing to submit a prior authorization through the Bridge program. Not every provider will be familiar with the program's specifics yet, so being proactive helps.
Gather your documentation. Prior authorization will require clinical documentation supporting your eligibility — BMI measurement, weight-related comorbidities, and evidence that you're engaged in lifestyle modification. Having recent lab work and medical records organized will streamline the process.
Understand your current coverage. Check whether your Part D plan already covers any GLP-1 medications. Some plans have begun including GLP-1 coverage independently of the Bridge program. If your plan covers a medication, that may be a faster path than the Bridge's prior authorization process.
Know that the Bridge is temporary. The program runs through December 31, 2027. If you start medication through the Bridge, you should plan for the possibility that you'll need to transition to Part D coverage or another payment mechanism after that date. CMS will likely provide guidance on transition planning as the program matures.
The Bigger Picture for Telehealth Access
The Bridge program creates both opportunities and challenges for telehealth GLP-1 platforms. On the opportunity side, telehealth providers can serve Medicare beneficiaries who prefer the convenience of remote care. On the challenge side, the program's emphasis on FDA-approved medications and prior authorization may not align with telehealth platforms built primarily around compounded medications and streamlined intake processes.
For consumers, the net effect is positive: more coverage options, more competitive pricing, and more reason for platforms to invest in the clinical infrastructure that supports quality care. The Medicare population's entry into the GLP-1 market at scale is likely to accelerate pricing competition and raise the bar for what telehealth platforms need to offer.
The Bottom Line
If you're a Medicare beneficiary, July 2026 is a date worth circling. The GLP-1 Bridge program won't be perfect — prior authorization processes can be slow, initial rollout may have friction, and the program's temporary nature creates uncertainty. But it represents a fundamental change in how the largest health insurance program in the country treats obesity. That change benefits not just Medicare patients, but everyone who stands to gain from a healthcare system that takes weight management more seriously.